company background image
LUPIN logo

Lupin NSEI:LUPIN Stock Report

Last Price

₹1.62k

Market Cap

₹737.2b

7D

0.3%

1Y

147.8%

Updated

28 Mar, 2024

Data

Company Financials +

LUPIN Stock Overview

Lupin Limited, a pharmaceutical company, develops, produces, markets, and sells a range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs) in India and internationally.

LUPIN fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance3/6
Financial Health6/6
Dividends2/6

Rewards

Risk Analysis

No risks detected for LUPIN from our risk checks.

Lupin Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Lupin
Historical stock prices
Current Share Price₹1,616.80
52 Week High₹1,704.25
52 Week Low₹628.00
Beta0.67
1 Month Change-0.36%
3 Month Change22.21%
1 Year Change147.82%
3 Year Change57.43%
5 Year Change104.90%
Change since IPO19,972.00%

Recent News & Updates

Here's Why Lupin (NSE:LUPIN) Can Manage Its Debt Responsibly

Mar 03
Here's Why Lupin (NSE:LUPIN) Can Manage Its Debt Responsibly

Earnings Beat: Lupin Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Feb 10
Earnings Beat: Lupin Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Recent updates

Here's Why Lupin (NSE:LUPIN) Can Manage Its Debt Responsibly

Mar 03
Here's Why Lupin (NSE:LUPIN) Can Manage Its Debt Responsibly

Earnings Beat: Lupin Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Feb 10
Earnings Beat: Lupin Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Lupin Limited's (NSE:LUPIN) Share Price Could Signal Some Risk

Jan 19
Lupin Limited's (NSE:LUPIN) Share Price Could Signal Some Risk

Is Lupin (NSE:LUPIN) Using Too Much Debt?

Nov 10
Is Lupin (NSE:LUPIN) Using Too Much Debt?

Is Lupin (NSE:LUPIN) Using Too Much Debt?

Jun 23
Is Lupin (NSE:LUPIN) Using Too Much Debt?

Here's Why Lupin (NSE:LUPIN) Can Manage Its Debt Responsibly

Mar 24
Here's Why Lupin (NSE:LUPIN) Can Manage Its Debt Responsibly

Lupin's (NSE:LUPIN) Dividend Is Being Reduced To ₹4.00

Jul 08
Lupin's (NSE:LUPIN) Dividend Is Being Reduced To ₹4.00

Is Lupin Limited (NSE:LUPIN) Worth ₹756 Based On Its Intrinsic Value?

Mar 27
Is Lupin Limited (NSE:LUPIN) Worth ₹756 Based On Its Intrinsic Value?

Lupin (NSE:LUPIN) Could Easily Take On More Debt

Jan 22
Lupin (NSE:LUPIN) Could Easily Take On More Debt

Does Lupin (NSE:LUPIN) Have A Healthy Balance Sheet?

Sep 16
Does Lupin (NSE:LUPIN) Have A Healthy Balance Sheet?

Shareholder Returns

LUPININ PharmaceuticalsIN Market
7D0.3%2.7%2.5%
1Y147.8%63.9%47.3%

Return vs Industry: LUPIN exceeded the Indian Pharmaceuticals industry which returned 63.9% over the past year.

Return vs Market: LUPIN exceeded the Indian Market which returned 47.3% over the past year.

Price Volatility

Is LUPIN's price volatile compared to industry and market?
LUPIN volatility
LUPIN Average Weekly Movement3.5%
Pharmaceuticals Industry Average Movement5.9%
Market Average Movement6.6%
10% most volatile stocks in IN Market10.1%
10% least volatile stocks in IN Market4.0%

Stable Share Price: LUPIN has not had significant price volatility in the past 3 months.

Volatility Over Time: LUPIN's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
196820,933Vinita Guptahttps://www.lupin.com

Lupin Limited, a pharmaceutical company, develops, produces, markets, and sells a range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs) in India and internationally. It offers formulations for use in the therapeutic areas of cardiovascular, diabetology, asthma, pediatrics, central nervous system, gastrointestinal, anti-infective, nonsteroidal anti-inflammatory drug therapy, respiratory, women’s health, and anti-tuberculosis. The company is also involved in the provision of biosimilars; over-the-counter products; specialty products; and drug discovery and development programs in the therapeutic areas of oncology, immunology, and metabolic disorders, as well as bio clinical research activities.

Lupin Limited Fundamentals Summary

How do Lupin's earnings and revenue compare to its market cap?
LUPIN fundamental statistics
Market cap₹737.22b
Earnings (TTM)₹17.91b
Revenue (TTM)₹194.80b

41.2x

P/E Ratio

3.8x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
LUPIN income statement (TTM)
Revenue₹194.80b
Cost of Revenue₹72.72b
Gross Profit₹122.08b
Other Expenses₹104.17b
Earnings₹17.91b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)39.30
Gross Margin62.67%
Net Profit Margin9.19%
Debt/Equity Ratio28.4%

How did LUPIN perform over the long term?

See historical performance and comparison

Dividends

0.2%

Current Dividend Yield

42%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.